- Home
- NSTS vs TENX Comparison
NSTS vs TENX Comparison
Compare NSTS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | TENX |
|---|---|---|
| Founded | 1921 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.4M | 56.2M |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | NSTS | TENX |
|---|---|---|
| Price | $12.50 | $12.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 1.5K | ★ 177.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 96.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $256,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.73 | $4.64 |
| 52 Week High | $13.06 | $18.38 |
Technical Indicators
Market Signals| Indicator | NSTS | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 45.58 |
| Support Level | $12.19 | $12.17 |
| Resistance Level | $12.26 | $13.14 |
| Average True Range (ATR) | 0.16 | 0.78 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 19.64 | 34.65 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.